

C1 date? 95. (Amended) A therapeutic composition, comprising a first isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;

(b) a polypeptide comprising at least part of a sequence as described in (a) above and has an epitope in common therewith; and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith;

wherein said composition can be used to reduce an allergic response to a cat antigen in an individual sensitive to said antigen.

C2 97. (Amended) A composition according to claim 95, further comprising a second isolated polypeptide that is different from the first polypeptide and which is selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:11, or SEQ ID NO:12;

(b) a polypeptide comprising at least a portion of an amino acid sequence as described in (a) above and has an epitope in common therewith; and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith.

C3 101. (Amended) An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;

(b) a polypeptide comprising at least a part of a sequence as described in (a) above and has an epitope in common therewith; and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith.